What is it about?
Parkinson disease (PD) is the most common neurodegenerative movement disorder. Although much progress has been made in understanding the underlying biology of the disease this has not translated to disease modifying therapies. There is an ever enlarging body of evidence that chaperone-mediated autophagy (CMA; a protein degradation pathway) and PD. Here we summarise these links and discuss how CMA is a promising therapeutic target in PD.
Featured Image
Why is it important?
We provide an up-to-date summary of the work linking chaperone-mediated autophagy (CMA) to Parkinson disease (PD). We discuss how some of the newly discovered CMA regulatory pathways may be therapeutically targeted to boost CMA function, and how this may be beneficial in PD.
Perspectives
We hope this article will highlight the importance of chaperone-mediated autophagy as a potential therapeutic target in Parkinson disease.
Philip Campbell
University College London
Read the Original
This page is a summary of: Chaperone-mediated autophagy as a therapeutic target for Parkinson disease, Expert Opinion on Therapeutic Targets, September 2018, Taylor & Francis,
DOI: 10.1080/14728222.2018.1517156.
You can read the full text:
Contributors
The following have contributed to this page
